Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 1.00 |
| ▸ | LGALS1 | P09382 | 9/20 | 1.00 |
| ▸ | LGALS9 | O00182 | 7/20 | 0.71 |
| ▸ | LGALS8 | O00214 | 7/20 | 0.71 |
| ▸ | LGALS7; LGALS7B | P47929 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067559 | 0.84 | LGALS3 (0.74) | LGALS3LGALS1LGALS9LGALS8LGALS7; LGALS7B | |
| SCHEMBL9949021 | 0.82 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8LGALS7; LGALS7B | |
| SCHEMBL15883834 | 0.82 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8LGALS7; LGALS7B | |
| SCHEMBL10067561 | 0.82 | LGALS3 (1.00) | LGALS3LGALS1LGALS9LGALS8LGALS7; LGALS7B | |
| SCHEMBL19580099 | 0.82 | LGALS3 (0.73) | LGALS3LGALS1LGALS9LGALS8LGALS7; LGALS7B | |
| SCHEMBL13404786 | 0.79 | LGALS3 (0.87) | LGALS3LGALS1LGALS9LGALS8LGALS7; LGALS7B | |
| SCHEMBL16258796 | 0.79 | LGALS3 (0.87) | LGALS3LGALS1LGALS9LGALS8LGALS7; LGALS7B | |
| SCHEMBL3281932 | 0.79 | LGALS3 (0.87) | LGALS3LGALS1LGALS9LGALS8LGALS7; LGALS7B | |
| SCHEMBL13385534 | 0.79 | LGALS3 (0.87) | LGALS3LGALS1LGALS9LGALS8LGALS7; LGALS7B | |
| SCHEMBL9950117 | 0.77 | LGALS3 (0.63) | LGALS3LGALS1LGALS9LGALS8LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424873-B1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (SE) | 2017-11-15 | — | — | EP | disclosed |
| US-20140200190-A1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (SE) | 2014-07-17 | — | — | US | disclosed |
| EP-2424873-A1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | Forskarpatent I SYD AB (SE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126435-A1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | FORSKARPATENT I SYD AB (SE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200190-A1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885LGALS9 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.